Disc Medicine (NASDAQ:IRON) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Disc Medicine (NASDAQ:IRON) in a report released on Wednesday, Marketbeat reports. The firm issued a buy rating and a $89.00 target price on the stock.

Other equities research analysts have also issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Disc Medicine in a research note on Monday, September 16th. Wells Fargo & Company started coverage on shares of Disc Medicine in a research note on Thursday, August 22nd. They issued an “overweight” rating and a $75.00 price target on the stock. Wedbush reiterated an “outperform” rating and set a $57.00 price objective on shares of Disc Medicine in a research note on Friday, August 9th. Scotiabank started coverage on shares of Disc Medicine in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $62.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $85.00 price objective on shares of Disc Medicine in a research note on Tuesday, October 15th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Disc Medicine has an average rating of “Moderate Buy” and a consensus price target of $66.40.

Disc Medicine Stock Up 0.0 %

IRON opened at $46.01 on Wednesday. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -12.54 and a beta of 0.59. Disc Medicine has a fifty-two week low of $25.60 and a fifty-two week high of $77.60. The company’s 50-day moving average price is $48.92 and its 200 day moving average price is $42.13.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.08. Research analysts anticipate that Disc Medicine will post -4.19 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Amalgamated Bank grew its position in Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after buying an additional 247 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Disc Medicine by 45.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after buying an additional 337 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Disc Medicine in the second quarter worth approximately $129,000. SG Americas Securities LLC boosted its stake in Disc Medicine by 44.2% in the 2nd quarter. SG Americas Securities LLC now owns 4,071 shares of the company’s stock worth $183,000 after purchasing an additional 1,247 shares during the period. Finally, ProShare Advisors LLC acquired a new position in Disc Medicine in the 1st quarter worth approximately $211,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.